Other News

Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors

Financial by 0 comments

KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company’s annual general meeting of shareholders held earlier this month. “I am pleased to welcome Dr. Kwo to the Kestra board of directors,” said Brian Webster, President and CEO of Kestra Medical Technologies. “As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes. Her expertise and perspective will be invaluable as we accelerate adoption of our lifesaving Cardiac Recovery System platform.” Dr. Kwo currently serves as Chief Commercial Officer of Everly Health, Inc, a diagnostics-driven digital healthcare company. She previously served as Deputy Chief Clinical Officer for Anthem, VP and GM of Provider Networks at American Well, and Entrepreneur in Residence at Harvard Medical School’s Office of Technology Development. She has also founded multiple venture-backed companies, including the educational platform New Pathway and digital healthcare company InfiniteMD. Dr. Kwo is board certified in preventive care and occupational medicine and remains active as a practicing physician. She earned her M.D. from Harvard Medical School, an M.P.H. from the Harvard T.H. Chan School of Public Health, an M.B.A. from Harvard Business School, and a B.A. from Stanford University. “I’m honored to join Kestra’s board of directors at such a pivotal time,” said Dr. Kwo. “Kestra’s commitment to protecting patients through innovation in cardiac recovery deeply resonates with me. I look forward to contributing my experience in digital health and care-model innovation to help advance the company’s mission and expand its impact for patients and providers.” About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com

Continue Reading →

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Peripheral/Endo by 0 comments

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated in CKD, discovered in pre-clinical studies led by Dr. Justin Chun The Company has filed both composition and method of use patents relating to the CKD platform. The Arch CKD program will be led by Dr. Justin Chun, who joins the Company as a Principal Scientist CKD is largely an unmet medical need, currently affecting more than 800 million people worldwide and approximately 35 to 38 million in the U.S. TORONTO, Sept. 17, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD). The platform includes recently filed patents protecting new compositions and methods targeting a novel mechanism of action involving interleukin-32 (IL-32), which is directly implicated in the progression of CKD. Farris Smith, Strategic Advisor to Arch and former CFO of Novo Nordisk Canada, said, “This new chronic kidney disease program expands the commercial potential of Arch’s kidney drug development pipeline. The assets underlying the CKD program could provide novel, on-target treatment options for a significant unmet need in a major pharmaceutical market. Combined with Arch’s existing acute kidney injury programs, Arch is better positioned for potential new partnership opportunities that can accelerate development and drive long-term value for the Company.” Richard Muruve, CEO of Arch Biopartners, said, “Our entry into the CKD drug development business is a natural evolution for our team that has a strong core competency in nephrology. Today’s news makes Arch Biopartners’ kidney drug portfolio more vital to patients and more valuable to the pharmaceutical industry.” Arch obtained the new CKD assets through the acquisition of all outstanding shares of Lipdro Therapeutics Inc. (Lipdro), a private Alberta based company and arm’s length to the Company, in return for 250,000 common shares of Arch at a deemed price of $1.85 per common share and a royalty on net sales in the future, and subject to final approval by the TSX Venture Exchange. Dr. Justin Chun, MD, PhD, founder and 100% owner of Lipdro, joins the Company as a Principal Scientist to lead development of the new Arch CKD platform. The common shares, when issued to Dr. Chun following today’s announcement, will be subject to a four month hold period. The therapeutic platform acquired by Arch specifically targets interleukin-32 (IL-32), a non-classical cytokine involved in regulating inflammation and immune responses. In pre-clinical studies, Dr. Chun and his scientific team discovered that IL-32 is directly implicated in the pathogenesis of diabetic CKD. New drug compositions were subsequently invented through a collaboration involving the National Research Council of Canada (NRC), Lipdro, and Arch scientists, and exclusively licensed to Arch by the NRC. Additional therapeutic approaches involving IL-32 were developed and patented by Dr. Chun and Arch scientists and assigned to Arch. Dr. Daniel Muruve, Chief Science Officer at Arch Biopartners and Professor, Cumming School of Medicine, University of Calgary, said, “We are excited to welcome Dr. Chun to the Arch science team as a Principal Scientist and leader of the IL-32 CKD program. His deep scientific knowledge as a nephrologist and his leading expertise in working with patient-derived kidney organoids will be invaluable as Arch develops novel therapeutics targeting chronic kidney disease.” These patents are a significant addition to Arch’s kidney drug asset portfolio. The IL-32 CKD program deepens the Company’s portfolio for developing new treatments for kidney diseases and injury. The new program introduces a novel therapeutic approach for diabetic CKD, the most common cause of kidney failure globally. The therapeutic platform is based on a mechanistic understanding of disease pathways and builds on Arch’s expertise in renal inflammation and organ protection. Dr. Chun said, “Targeting the underlying mechanisms of inflammation and fibrosis that drive CKD is critical for preventing irreversible structural organ damage and slowing the progression toward kidney failure. In this context, our discovery of IL-32 as an intracellular, unconventional cytokine that links metabolic dysregulation to chronic inflammation represents a promising therapeutic target and opens new avenues for halting the progression of CKD, including diabetic kidney disease.” An overview of the IL-32 mechanism of action related to diabetic-CKD is summarized by Dr. Chun and his collaborators in the following abstract published in the Journal of the American Society of Nephrology: “IL-32 Is a Lipid Droplet-Associated Mediator of Tubular Injury in Diabetic Kidney Disease” Chronic Kidney Disease (CKD) CKD affects more than 800 million people worldwide1,2 and approximately 35 to 38 million in the U.S.3. Diabetes is the leading cause, responsible for an estimated 30% to 40% of all CKD cases4. Diabetic CKD leads to kidney failure, and several other major comorbidities, including cardiovascular disease. Many current renal therapies are based on unanticipated ‘off-target’ actions of drugs originally designed to control blood pressure, blood sugar, and cardiovascular complications5,6 rather than targeting specific biological pathways in the kidney that drive disease7,8. Arch’s newly acquired ‘on-target’ CKD platform stands apart from many drugs in use today and may represent the next generation of CKD candidates for clinical development in the pharmaceutical industry. About Dr. Justin Chun Dr. Chun, MD, PhD is an Associate Professor and Clinician Scientist at the Cumming School of Medicine, University of Calgary, and Assistant Director of the Precision Medicine in Nephrology Program at the Snyder Institute for Chronic Diseases. He also co-directs the Human Organoid Innovation Hub, where his research focuses on using patient-derived kidney organoids and primary kidney cells to study glomerular diseases and diabetic kidney disease. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation- and toxin-induced kidney injury. The company’s programs include a pre-clinical chronic kidney disease platform targeting IL-32 (announced today), LSALT peptide, a first-in-class DPEP1 inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. For more details about the Company’s science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for news as it happens. The Company has 66,106,366 common shares outstanding. For more information, please contact: Aaron BensonDirector of CommunicationsArch Biopartners, Inc. 647-428-7031 Send a message and subscribe for email alerts at: www.archbiopartners.com/contact-us Citations: Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18. PMID: 35529086; PMCID: PMC9073222Francis, A., Harhay, M.N., Ong, A.C.M. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 20, 473–485 (2024). doi: 10.1038/s41581-024-00820-6Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2023Ma X, Liu R, Xi X, Zhuo H, Gu Y. Global burden of chronic kidney disease due to diabetes mellitus, 1990–2021, and projections to 2050. Front Endocrinol (Lausanne). 2025;16 doi: 10.3389/fendo.2025.1513008Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008. PMID: 36272764Francis, A., Harhay, M.N., Ong, A.C.M. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 20, 473–485 (2024). doi: 10.1038/s41581-024-00820-6Zoccali C, Vanholder R, Massy Z. et al. The systemic nature of CKD. Nat Rev Nephrol 13, 344–358 (2017). doi: 10.1038/nrneph.2017.52.Baigent, ColinAnker, Stefan D. et al. Impact of diabetes on the effects of sodium–glucose cotransporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet. 2022;400(10365):1788–1801. doi: 10.1016/S0140-6736(22)02074-8. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company’s future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management’s current expectations and beliefs, including certain factors and assumptions, as described in the Company’s most recent annual audited financial statements and related management discussion and analysis under the heading “Business Risks and Uncertainties”. As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company’s most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (“SEDAR”) website at www.sedarplus.ca. The scientific and medical content of this release has been approved by the Company’s Chief Science Officer Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Continue Reading →

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

Financial by 0 comments

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $550.0 million. Key elements of the transaction include: Primarily a refinancing transaction of the 3.50% convertible senior notes due 2027 (the “2027 notes”), which extends the maturity of the refinanced debt to 2031Achieved a lower coupon of 1.75% and a higher conversion price of approximately $68.42 compared to the 2027 notesRetiring approximately $399.5 million of the 2027 notesAny remaining proceeds will be used to support the potential commercial launch of aficamten and for general corporate purposes, including potentially to retire the remaining 2027 notes before or at maturity of those notes that are not exchanged and refinanced pursuant to this transaction The issuance and sale of the notes are scheduled to settle on September 19, 2025, subject to customary closing conditions. Cytokinetics also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $100.0 million aggregate principal amount of notes. The notes will be senior, unsecured obligations of Cytokinetics. The notes will accrue interest at an annual rate of 1.75%, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2026. The notes will mature on October 1, 2031, unless earlier converted, redeemed or repurchased by Cytokinetics. Before July 1, 2031, noteholders will have the right to convert their notes only in certain circumstances. From and after July 1, 2031, noteholders may convert all or any portion of their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Cytokinetics will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Cytokinetics’ election. The initial conversion rate is 14.6156 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $68.42 per share of common stock. The initial conversion price represents a premium of approximately 37.5% over the last reported sale price of $49.76 per share of Cytokinetics’ common stock on September 16, 2025. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. Cytokinetics’ may not redeem the notes at its election at any time before October 6, 2028. The notes will be redeemable, in whole or in part (subject to certain limitations), at Cytokinetics’ option at any time, and from time to time, on a redemption date on or after October 6, 2028 and, in the case of any partial redemption, on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if (i) the notes are “freely tradable” (as defined in the indenture for the notes) as of the date Cytokinetics sends the related redemption notice and all accrued and unpaid additional interest, if any, has been paid in full as of the first interest payment date occurring on or before the date such notice is sent and (ii) the last reported sale price per share of Cytokinetics’ common stock exceeds 130% of the conversion price for a specified period of time. If a “fundamental change” (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Cytokinetics to repurchase their notes at a cash repurchase price equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. Use of Proceeds: Cytokinetics estimates that the net proceeds from the offering will be approximately $632.0 million (or approximately $729.4 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and Cytokinetics’ estimated offering expenses. Cytokinetics intends to use: approximately $402.5 million of the net proceeds from the offering to pay the cash portion of the consideration in the note exchange transactions as described below; andthe remainder of the net proceeds of this offering will be used (a) to support the potential commercial launch of aficamten, (b) to continue and expand the development program for aficamten, (c) to advance its development and research pipeline, and (d) for general corporate purposes, including potentially to retire the remaining 2027 notes before or at maturity of those notes that are not exchanged and refinanced pursuant to this transaction and working capital. Cytokinetics expects to use approximately $402.5 million of the net proceeds from the offering and to issue 2,168,806 shares of its common stock in exchange for approximately $399.5 million aggregate principal amount of the 2027 notes in privately negotiated transactions (each, a “note exchange transaction”) entered into concurrently with the pricing of the offering. The terms of each note exchange transaction will depend on a variety of factors, including the market price of Cytokinetics’ common stock and the trading price of the 2027 notes at the time of such note exchange transactions. No assurance can be given as to how much, if any, of the 2027 notes will be exchanged or the terms on which they will be exchanged. This press release is not an offer to exchange the 2027 notes, and the offering of the notes is not contingent upon the note exchange transactions. In connection with any note exchange transaction, Cytokinetics expects that holders of the 2027 notes who agree to have their 2027 notes exchanged and who have hedged their equity price risk with respect to such 2027 notes (the “hedged holders”) will, concurrently with, or shortly after, the pricing of the notes, unwind all or part of their hedge positions by buying Cytokinetics’ common stock and/or entering into or unwinding various derivative transactions with respect to its common stock. The amount of Cytokinetics’ common stock to be purchased by the hedged holders or the notional number of shares of Cytokinetics’ common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of Cytokinetics’ common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of Cytokinetics’ common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price for the notes. Cytokinetics cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or its common stock. The offer and sale of the notes, any shares of common stock issuable upon conversion of the notes and any shares of common stock issuable in connection with any note exchange transaction have not been, and will not be, registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any state or jurisdiction. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the completion of the offering, the expected amount and intended use of the net proceeds and the timing or amount of any exchanges of the 2027 notes by Cytokinetics and the potential impact of the foregoing or related transactions on the market price of Cytokinetics’ common stock or the price of the notes. Forward-looking statements represent Cytokinetics’ current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the closing conditions related to the offering and risks relating to Cytokinetics’ business, including in its Annual Report on Form 10-K for the period ended December 31, 2024, filed with the SEC on February 27, 2025 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025, filed with the SEC on May 6, 2025 and August 7, 2025, respectively, and other filings that Cytokinetics makes from time to time with the SEC. Cytokinetics may not consummate the offering or the note exchange transactions described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Cytokinetics does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law. Contact:Cytokinetics, Inc.Diane WeiserSenior Vice President, Corporate Affairs(650) 624-3060

Continue Reading →

NobleStitch™ Suture-Mediated PFO Closure Demonstrates Superior Long-Term Safety and Outcomes in Largest Cohort to Date

Coronary/Structural Heart by 0 comments

New data show zero device-related complications or atrial fibrillation, no recurrent stroke or TIA, with a cohort 40% larger than Gore and Amplatzer device studies FOUNTAIN VALLEY, Calif., Sept. 16, 2025 /PRNewswire/ — NobleStitch™, the deviceless suture-mediated patent foramen ovale…

Continue Reading →

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Financial by 0 comments

MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution.

Continue Reading →

Peerbridge Health Announces Funding Round Close, FDA 510(k) Submission of Next-Gen Device Appoints – Dan Reuvers to the board and expands sales team

Financial by 0 comments

Despite heart disease being the leading cause of death in the U.S., millions lack access to affordable, accurate diagnostics. Peerbridge Health, the company transforming how heart disease is diagnosed, is working to close that gap and announced a series of milestones today that will move it closer to that goal. […]

Continue Reading →

Lightning Bolt 6X with Trax Now Available in 150 cm, Bringing the Power of CAVT to More Distal Anatomy Below the Knee

Peripheral/Endo by 0 comments

Penumbra recently announced that Lightning Bolt® 6X with TraX,™ designed to reach and confidently remove thrombus below the knee, is now available in a 150 cm catheter length. This longer option brings the power and efficiency of Penumbra’s Computer Assisted Vacuum Thrombectomy (CAVT™) to the distal arteries in the body. “Lightning Bolt […]

Continue Reading →

Stroke diagnostics innovator Wellumio seeks investors to transform stroke recovery

Neuro by 0 comments

Stroke diagnostics innovator Wellumio seeks investors to transform stroke recovery Wellumio is transforming stroke care with portable brain scans to rapidly detect acute stroke that cuts diagnosis time and unlocks treatment in the ‘golden hour’ when every second counts WELLINGTON, New Zealand, September 16, 2025 – Wellumio, a New Zealand-based medical […]

Continue Reading →
1 … 46 47 48 49 50 … 1,298